HFM
CRDL

Hartford Financial Management’s Cardiol Therapeutics CRDL Stock Holding History

Hartford Financial Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,000
Closed -$3.88K – 353
2025
Q1 		$3.88K Hold
4,000
– – ﹤0.01% 313
2024
Q4 		$5.12K Hold
4,000
– – ﹤0.01% 319
2024
Q3 		$7.92K Hold
4,000
– – ﹤0.01% 311
2024
Q2 		$8.08K Buy
+4,000
New +$8.49K ﹤0.01% 309

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return

Hartford Financial Management's CRDL Position: Q2 2025 in Review

Hartford Financial Management sold out of Cardiol Therapeutics (CRDL) in Q2 2025, closing a stake of 4,000 shares — an estimated $3.88K sold.

Hartford Financial Management first reported a position in CRDL in Q2 2024 and held it in 4 quarters. The position peaked at $8.08K in Q2 2024. 38 funds tracked by Wall St. Rank hold CRDL as of Q2 2025.

  • Hartford Financial Management reported no remaining Cardiol Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hartford Financial Management sold 4,000 Cardiol Therapeutics shares in Q2 2025, an estimated $3.88K.
  • Hartford Financial Management first reported a position in Cardiol Therapeutics in Q2 2024 and held it in 4 quarters.
  • Hartford Financial Management's Cardiol Therapeutics position peaked at $8.08K in Q2 2024.
  • 38 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2025.

Based on Hartford Financial Management's 13F filing for Q2 2025, filed 31 Jul 2025.